As of Nov 25
| +0.14 / +1.25%|
The 4 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 15.50, with a high estimate of 21.00 and a low estimate of 8.00. The median estimate represents a +36.80% increase from the last price of 11.33.
The current consensus among 4 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.